Title |
Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury
|
---|---|
Published in |
CNS Drugs, October 2012
|
DOI | 10.1007/s40263-012-0013-2 |
Pubmed ID | |
Authors |
Edward Tobinick, Nancy M. Kim, Gary Reyzin, Helen Rodriguez-Romanacce, Venita DePuy |
Abstract |
Brain injury from stroke and traumatic brain injury (TBI) may result in a persistent neuroinflammatory response in the injury penumbra. This response may include microglial activation and excess levels of tumour necrosis factor (TNF). Previous experimental data suggest that etanercept, a selective TNF inhibitor, has the ability to ameliorate microglial activation and modulate the adverse synaptic effects of excess TNF. Perispinal administration may enhance etanercept delivery across the blood-CSF barrier. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Singapore | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 227 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 2% |
United Kingdom | 2 | <1% |
Spain | 1 | <1% |
Unknown | 219 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 32 | 14% |
Student > Bachelor | 30 | 13% |
Student > Master | 29 | 13% |
Researcher | 25 | 11% |
Student > Doctoral Student | 15 | 7% |
Other | 44 | 19% |
Unknown | 52 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 52 | 23% |
Nursing and Health Professions | 25 | 11% |
Psychology | 23 | 10% |
Agricultural and Biological Sciences | 19 | 8% |
Neuroscience | 15 | 7% |
Other | 30 | 13% |
Unknown | 63 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2022.
All research outputs
#1,458,482
of 25,483,400 outputs
Outputs from CNS Drugs
#108
of 1,389 outputs
Outputs of similar age
#9,139
of 202,176 outputs
Outputs of similar age from CNS Drugs
#6
of 138 outputs
Altmetric has tracked 25,483,400 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,389 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.